Bedrijfsoverzicht
Braskem S.A. is a major entity within the Brazilian chemical landscape, engaging in the comprehensive manufacture, sale, import, and export of chemicals, petrochemicals, and fuels. The company operates specifically within the Basic Materials sector and the Chemicals industry, a classification that signifies its role in producing essential raw materials and intermediates required for downstream manufacturing processes across various industrial applications. In terms of market scale, Braskem holds a market capitalization of $1.51B and reported total revenue of $70.72B over the trailing twelve months, though the specific employee count is not disclosed in available records. These financial metrics, particularly the substantial revenue figure relative to the market capitalization, indicate a company with significant operational scale where valuation multiples may be heavily influenced by sector-specific cyclical factors or accounting treatments regarding debt and earnings. The disparity between the high revenue volume and the lower market cap suggests that the market prices the stock based on current profitability constraints rather than revenue generation alone, highlighting the capital-intensive nature of the petrochemical value chain.
Financiële gezondheid
The company reported revenue of $70.72B for the trailing twelve months, yet generated a net income of $-9,880,000,512, a stark divergence that reveals a cost structure where expenses, including interest charges or one-time provisions, significantly outweigh gross profits. Despite the negative net income, the company maintains an EBITDA of $4.02B, indicating that operational cash generation before financing costs remains positive, although this does not fully offset the bottom-line losses. However, free cash flow stands at $-5,425,999,872, which implies that capital expenditures and working capital requirements are currently exceeding operational cash inflows, thereby limiting the company's immediate financial flexibility for discretionary spending or acquisitions. Margin analysis shows a gross margin of 4.8%, reflecting the highly competitive pricing environment typical of commodity chemicals, an operating margin of 15.0% which suggests efficiency in controlling operating expenses relative to revenue, and a profit margin of -14.0% that confirms the loss-making status of the bottom line. Regarding liquidity, the company holds $11.84B in cash against total debt of $71.32B, resulting in a debt-to-equity ratio that is not calculable due to the negative equity position, which characterizes a highly leveraged balance sheet dependent on refinancing or asset sales. The current ratio is 0.76, a figure below 1.0 that indicates the company's current assets are insufficient to cover its current liabilities without relying on external financing or inventory liquidation. Return on Equity is not available due to the negative equity base, while Return on Assets is recorded at 0.2%, a metric that reveals management is currently generating minimal returns on the total asset base deployed.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to negative earnings, whereas the forward P/E is listed at -4.74, a negative multiple that implies the market currently expects earnings to remain negative or suggests a valuation model that accounts for significant future dilution or restructuring costs. The price-to-book ratio is -0.48, a negative figure indicating that the market values the company at a discount relative to its book value, which often occurs when liabilities exceed assets or when intangible assets are not fully captured on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.02 and an EV/EBITDA of 15.47, suggesting that the market values the firm primarily on its sales volume and adjusted earnings power rather than traditional profitability multiples. The stock has traded between a 52-week low of $2.32 and a 52-week high of $5.29; without a specific current price provided in the facts, the valuation range indicates a high degree of volatility and sensitivity to commodity price swings or credit rating changes. The beta of 0.75 indicates that the stock's price volatility is lower than the broader market, suggesting that Braskem moves less sharply than the general index, which is somewhat atypical for a leveraged cyclical stock but reflects a specific correlation pattern with the broader market index.
Growth & Income
Revenue growth year-over-year is -15.9%, while earnings growth is not available due to the lack of comparable prior period data in the current dataset, meaning a direct comparison of growth rates is impossible but the revenue contraction signals a challenging cyclical downturn or demand shock. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company retains all earnings or cash flows rather than distributing them to shareholders. This retention strategy, coupled with the negative net income, suggests that the company is prioritizing capital preservation, debt servicing, or reinvestment into growth initiatives over providing income to investors. Consequently, the overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, positioning Braskem as a pure-play exposure to capital appreciation potential during a cyclical recovery rather than a yield-generating investment vehicle.